A 65-year-old white woman presented with 9 months of intermittent “kaleidoscopic” visual disturbances and blurred vision upon awakening.Her medical history was significant for hypertension, ...
Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...
RegenXBio reported that dosing is complete in the AFFINITY pivotal Duchenne trial, with robust enrollment in the confirmatory study and encouraging Phase 1/2 data. At 18 months, treated boys showed a ...
Subretinal Cirovec topline data for wet AMD is projected for Q4 2026, serving as the basis for global regulatory submissions ...
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data ...
Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...
Researchers use single-cell analysis to show how transplanted neural stem cells interact with the retina to preserve vision in retinitis pigmentosa.
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting ...
The recent progress and future development of gene therapy could help patients with wet age-related macular degeneration maintain vision, according to a speaker at Retina 2026. Allen C. Ho, MD, of ...
Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results